VIVUS News

Dow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool on any article or visit www.djreprints.com Shares of Vivus are poised to rise or fall sharply later this month when its Qnexa weight-loss drug is ... (more)

Biotechnology companies spend an extraordinary amount of resources-capital, time, and personnel- to get to this point, a final dance with the FDA seeking drug approval.

YOU are not alone if you have never heard of Semper Vivus. It was a car that was created long before anyone alive today was born.

The bulk of the action has centered around the out-of-the-money March 9 strike, where nearly 3,197 puts have crossed the tape -- most of them between the ask and bid prices, making it difficult to discern whether they were bought or sold.

Many biotech firms produce little to no revenue, relying on sources of equity investment until they gain drug approval or a lucrative research deal.

MAKO Surgical : Summer Street Research reiterated its rating of Buy for this company and changed its price target from $35 to $39. Amazon.com : The Benchmark Company reiterated its rating of Buy for this company and changed its price target from $225 to $210. Intuitive Surgical : JMP Securities reiterated its rating of Mkt Outperform for this ... (more)

VIVUS, Inc. 's REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function /PRNewswire/ -- VIVUS, Inc.

Investment analysts at MLV & Co increased their price target on shares of VIVUS from $16.00 to $22.00 in a note issued to investors on Tuesday.